2013 has been a year of setbacks for the Indian pharma industry as the regulatory scrutiny has become tough, especially on Indian pharma companies because they have a bigger market share. It is, therefore, important for domestic companies to increase their investment in compliance of regulatory norms.
Pharma is one sector where India is widely accepted to have manufacturing competence. If that credibility is eroded, current plans to boost pharma exports to $20 billion by 2020 will turn into a pipe dream. Thus the Indian pharma must turn proactive and consider a self-regulatory body.
Keeping this in issue in mind, CPhI India brings to you the 3rd Annual Global Pharma Regulatory Summit to provide insights on the issues of regulatory compliance
Dr. Sumit Sen,
Boehringer Ingelheim India
Frances M. Zipp,